In recent years, PSMA-PET/CT has been the preferred staging modality for both primary and recurrent prostate cancer due to its superior sensitivity and specificity [4,5,6,7,8,9,10,11,12,13,14,15], especially in assessing extra-skeletal involvement such as nodal metastasis. The gene discussed is FOLH1; the disease is prostate cancer.